Arrowhead Pharmaceuticals, Inc.
ARWR
$79.04
$1.301.67%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/12/2026
-
Seeking Alpha - Long Ideas
5/12/2026
-
Seeking Alpha - Healthcare
5/12/2026
-
PR Newswire
5/12/2026
-
CNW Group - News Releases
5/12/2026
-
TipRanks Financial Blog
5/11/2026
-
The Cerbat Gem
5/11/2026
-
MarketBeat
5/10/2026
-
Simply Wall St
5/9/2026
-
MarketBeat
5/9/2026
-
TipRanks Financial Blog
5/8/2026
-
Simply Wall St
5/8/2026
-
The Cerbat Gem
5/8/2026
-
MarketBeat
5/8/2026
-
The Cerbat Gem
5/8/2026
-
MarketBeat
5/8/2026
-
SeekingAlpha
5/7/2026
-
MarketBeat
5/7/2026
-
Business Wire
5/7/2026
-
Zacks Investment Research
5/7/2026
-
Zacks Investment Research
5/7/2026
-
Zacks Investment Research
5/7/2026
-
Zacks Investment Research
5/7/2026
-
Tickeron - Stocks
5/7/2026
-
Tickeron - Stocks
5/6/2026
-
Seeking Alpha - Healthcare
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, May 7, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
626 304 3400
Address
177 East Colorado Boulevard
Pasadena, CA 91105
Pasadena, CA 91105
Country
Year Founded
Business Description
Sector
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in...
more